MOG cell-based assay detects non-MS patients with inflammatory neurologic disease

MOG cell-based assay detects non-MS patients with inflammatory neurologic disease

Objective: To optimize sensitivity and disease specificity of a myelin oligodendrocyte glycoprotein (MOG) antibody assay. Methods: Consecutive sera (n 5 1,109) sent for aquaporin-4 (AQP4) antibody testing were screened for MOG antibodies (Abs) by cell-based assays using either full-length human MOG...

Full description

Bibliographic Details
Main Authors:	Waters, P, Woodhall, M, O'Connor, K, Reindl, M, Lang, B, Sato, D, Juryńczyk, M, Tackley, G, Rocha, J, Takahashi, T, Misu, T, Nakashima, I, Palace, J, Fujihara, K, Leite, M, Vincent, A
Format:	Journal article
Language:	English
Published:	Lippincott, Williams and Wilkins 2015

Similar Items

International multicenter examination of MOG antibody assays
by: Reindl, M, et al.
Published: (2020)

Distinguishing the brain MRI features of MS, AQP4-and MOG-antibody disease.
by: Jurynczyk, M, et al.
Published: (2016)

Metabolomics reveals distinct, antibody-independent, molecular signatures of MS, AQP4-antibody and MOG-antibody disease.
by: Jurynczyk, M, et al.
Published: (2017)

Metabolomics reveals distinct, antibody-independent, molecular signatures of MS, AQP4-antibody and MOG-antibody disease
by: Jurynczyk, M, et al.
Published: (2017)

Anti-MOG Antibodies in Japanese Patients with Neuromyelitis Optica Spectrum Disorders
by: Sato, D, et al.
Published: (2014)

Brain lesion distribution criteria distinguish MS from AQP4-antibody NMOSD and MOG-antibody disease
by: Juryńczyk, M, et al.
Published: (2016)

Disease course and disability outcomes in MOG-antibody disease in the UK
by: Jurynczyk, M, et al.
Published: (2017)

Clinical presentation and prognosis in MOG-antibody disease: a UK study
by: Jurynczyk, M, et al.
Published: (2017)

Metabolomics reveals distinct, antibody-independent, molecular signatures of MS, AQP4-antibody and MOG-antibody disease
by: Maciej Jurynczyk, et al.
Published: (2017-12-01)

Frequency of MOG-IgG in cerebrospinal fluid versus serum
by: Pace, S, et al.
Published: (2021)

Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders.
by: Sato, D, et al.
Published: (2014)

Myelin injury without astrocytopathy in neuroinflammatory disorders with MOG antibodies.
by: Kaneko, K, et al.
Published: (2016)

Recent developments in MOG-IgG associated neurological disorders
by: Harald Hegen, et al.
Published: (2020-07-01)

Antibodies to MOG in adults with inflammatory demyelinating disease of the CNS
by: Waters, P, et al.
Published: (2015)

Recurrent optic neuritis associated with MOG antibody seropositivity
by: Chang, T, et al.
Published: (2017)

A multicenter comparison of MOG-IgG cell-based assays
by: Waters, P, et al.
Published: (2019)

We need to talk about MOG
by: Waters, P, et al.
Published: (2020)

RELAPSING AQP4 ANTIBODY NEGATIVE NMO WITH MOG ANTIBODIES
by: Elsone, L, et al.
Published: (2014)

A 41-year-old woman with acute weakness and encephalopathy associated with MOG antibodies.
by: Morris, K, et al.
Published: (2015)

Evaluation of brain lesion distribution criteria at disease onset in differentiating MS from NMOSD and MOG-IgG-associated encephalomyelitis
by: Hyun, J, et al.
Published: (2018)

An international multicentre validation experiment for MOG antibodies
by: Reindl, M, et al.
Published: (2018)

Distinct brain imaging characteristics of autoantibody-mediated CNS conditions and multiple sclerosis
by: Jurynczyk, M, et al.
Published: (2017)

Isolated new onset 'atypical' optic neuritis in the NMO clinic: serum antibodies, prognoses and diagnoses at follow-up.
by: Piccolo, L, et al.
Published: (2016)

Overlapping CNS inflammatory diseases: differentiating features of NMO and MS.
by: Juryńczyk, M, et al.
Published: (2015)

Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica
by: Waters, P, et al.
Published: (2016)

The Importance of Aquaporin-4 Antibody Assays in Patients beyond the Diagnostic Criteria for Neuromyelitis Optica Spectrum Disorders
by: Sato, D, et al.
Published: (2013)

Refining cell-based assay to detect MOG-IgG in patients with central nervous system inflammatory diseases
by: Kim, Y, et al.
Published: (2020)

Chronic neuropathic pain severity is determined by lesion level in aquaporin 4-antibody-positive myelitis
by: Tackley, G, et al.
Published: (2016)

MOG encephalomyelitis: international recommendations on diagnosis and antibody testing
by: Jarius, S, et al.
Published: (2018)

No strong HLA association with MOG antibody disease in the UK population
by: Grant-Peters, M, et al.
Published: (2021)

Myelin oligodendrocyte glycoprotein antibodies in neurological disease
by: Reindl, M, et al.
Published: (2018)

Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan.
by: Kitley, J, et al.
Published: (2012)

Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan
by: Kitley, J, et al.
Published: (2012)

PREGNANCY OUTCOME IN AQUAPORIN-4 POSITIVE NEUROMYELITIS OPTICA SPECTRUM DISORDER: A MULTI-CENTER RETROSPECTIVE COHORT STUDY
by: Nour, M, et al.
Published: (2014)

The impact of neuromyelitis optica spectrum disorder on pregnancy outcome
by: Nour, M, et al.
Published: (2014)

MOG-IGG IN NMO AND NMO-LIKE DISORDERS
by: Luppe, S, et al.
Published: (2014)

Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patients
by: Whittam, DH, et al.
Published: (2020)

Classifying the antibody-negative NMO syndromes: Clinical, imaging, and metabolomic modeling
by: Yeo, T, et al.
Published: (2019)

MOG antibody disease with non-neurological involvement: A chance coincidence or a relevant association
by: Camelia Porey, et al.
Published: (2022-01-01)

Peripherally derived macrophages as major phagocytes in MOG encephalomyelitis
by: Kwon, Y, et al.
Published: (2019)